Optometrists in Clayton, GA Accepting Medicare
4 Optometrists found. Showing 1 - 4
 Dr. Alexa Reane Arencibia, OD Optometrist Medicare: Medicare Enrolled Practice Location: 21 Legacy Point, Clayton, GA 30525 Phone: 706-782-3535 |
 Clayton Family Eye Care Pc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 50 Earl St., Suite A, Clayton, GA 30525 Phone: 706-782-3535 Fax: 706-782-7525 |
 Dr. Stephen R Thurmond, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 50 Earl St, Suite A, Clayton, GA 30525 Phone: 706-782-3535 Fax: 706-782-7525 |
Dr. Ibry Dell Engram, OD Optometrist Medicare: Medicare Enrolled Practice Location: 1455 Hwy 441 South, Clayton, GA 30525 Phone: 706-782-6961 Fax: 706-782-6966 |
News Archive
Emergent BioSolutions acquires 55,000 square foot manufacturing facility from MdBio Foundation
Emergent BioSolutions Inc. announced today that it has completed the acquisition of a 55,000 square foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the City of Baltimore for a total purchase price of $8.2 million. The facility, located within the City of Baltimore, Maryland, previously operated as a Food and Drug Administration (FDA) licensed facility used by an experienced contract manufacturing organization (CMO) to produce a number of FDA approved products.
Botswana to implement pilot HIV/TB program, redesign malaria program
Botswana's Health Minister Lesego Motsumi on Monday presented a pilot program to address HIV/tuberculosis coinfection and support health workers who are treating patients with HIV/TB coinfection, Mmegi reports.
Home-based HIT appears to be effective for improving fitness in obese individuals
How much do you exercise? Government guidelines suggest that, in order to stay healthy, adults should perform at least 150 minutes of moderate aerobic activity every week - that's exercise that gets your breathing and heart rate up.
SARS-CoV-2 variants appear to arise independently of local transmission
Researchers at the University of Michigan in the United States have cautioned against only using within-host minor genetic variations to resolve the genomic epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin
BioInvent International AB and ThromboGenics NV announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism following orthopaedic surgery.
› Verified 2 days ago
Physical Therapists
Occupational Therapists
Chiropractors
Speech-Language Pathologists
Optometrists
Podiatrists